This is a working overview of half-life, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R agonist | Subtype most often linked to behavioural effects |
| Other reported targets | MC1R, MC3R, MC5R | Activity is not selective for a single subtype |
| Endogenous ligand class | Melanocortin peptides | Alpha-MSH and ACTH act on the same family |
| Peptide architecture | Cyclic heptapeptide | Lactam bridge between the aspartate and lysine residues |
| Central action | Inferred from animal models | Not directly measured in the human brain |
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
== External links == Protein-DNA binding: data, tools & models (annotated list, constantly updated) Abalone tool for modeling DNA-ligand interactions. DBD database of predicted transcription factors Uses a curated set of DNA-binding domains to predict transcription factors in all completely sequenced genomes DNA-Binding+Proteins at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
A Pew Research Center post-election analysis of voters who are listed as having voted in their state's voter turnout records who have also reported voting in a survey after the election similarly found a "more racially and ethnically diverse" electorate, one that was less engaged politically than in the four previous federal elections. More 2020 Trump voters (89%) than 2020 Biden voters (85%) also voted in 2024. 15% of those who voted for Biden in 2020 did not vote in the 2024 election. 78% of White voters supported Trump in 2024, a lower level of support for him among this group than in 2020 and 2016. Fewer Black voters supported Harris in 2024 than they did the Democratic candidates in the 2020 and 2016 elections.
=== EC 1.14.13 With NADH or NADPH as one donor, and incorporation of one atom of oxygen into the other donor === EC 1.14.13.1: salicylate 1-monooxygenase EC 1.14.13.2: 4-hydroxybenzoate 3-monooxygenase EC 1.14.13.3: Now EC 1.14.14.9, 4-hydroxyphenylacetate 3-monooxygenase EC 1.14.13.4: melilotate 3-monooxygenase EC 1.14.13.5: imidazoleacetate 4-monooxygenase EC 1.14.13.6: orcinol 2-monooxygenase EC 1.14.13.7: phenol 2-monooxygenase EC 1.14.13.8: flavin-containing monooxygenase EC 1.14.13.9: kynurenine 3-monooxygenase EC 1.14.13.10: 2,6-dihydroxypyridine 3-monooxygenase EC 1.14.13.11: Now EC 1.14.14.91, trans-cinnamate 4-monooxygenase EC 1.14.13.12: Now EC 1.14.14.92, benzoate 4-monooxygenase EC 1.14.13.13: Now classified as EC 1.14.15.18, calcidiol 1-monooxygenase EC 1.14.13.14: trans-cinnamate 2-monooxygenase EC 1.14.13.15: Now EC 1.14.15.15, cholestanetriol 26-monooxygenase EC 1.14.13.16: cyclopentanone monooxygenase EC 1.14.13.17: Now EC 1.14.14.23, cholesterol 7α-monooxygenase EC 1.14.13.18: 4-hydroxyphenylacetate 1-monooxygenase EC 1.14.13.19: taxifolin 8-monooxygenase EC 1.14.13.20: 2,4-dichlorophenol 6-monooxygenase EC 1.14.13.21: Now EC 1.14.14.82, flavonoid 3′-monooxygenase EC 1.14.13.22: cyclohexanone monooxygenase EC 1.14.13.23: 3-hydroxybenzoate 4-monooxygenase EC 1.14.13.24: 3-hydroxybenzoate 6-monooxygenase EC 1.14.13.25: methane monooxygenase (soluble) EC 1.14.13.26: Now classified as EC 1.14.18.4, phosphatidylcholine 12-monooxygenase EC 1.14.13.27: 4-aminobenzoate 1-monooxygenase EC 1.14.13.28: Now EC 1.14.14.93, 3,9-dihydroxypterocarpan 6a-monooxygenase EC 1.14.13.29: 4-nitrophenol 2-monooxygenase EC 1.14.13.30: Now EC 1.14.14.94, leukotriene-B4 20-monooxygenase EC 1.14.13.31: 2-nitrophenol 2-monooxygenase EC 1.14.13.32: albendazole monooxygenase EC 1.14.13.33: 4-hydroxybenzoate 3-monooxygenase (NAD(P)H) EC 1.14.13.34: leukotriene-E4 20-monooxygenase EC 1.14.13.35: anthranilate 3-monooxygenase (deaminating) EC 1.14.13.36: Now EC 1.14.14.96, 5-O-(4-coumaroyl)-D-quinate 3′-monooxygenase EC 1.14.13.37: Now EC 1.14.14.97, methyltetrahydroprotoberberine 14-monooxygenase EC 1.14.13.38: anhydrotetracycline monooxygenase EC 1.14.13.39: nitric-oxide synthase EC 1.14.13.40: anthraniloyl-CoA monooxygenase EC 1.14.13.41: Now EC 1.14.14.36, tyrosine N-monooxygenase EC 1.14.13.42: The activity is covered by EC 1.14.13.68, 4-hydroxyphenylacetaldehyde oxime monooxygenase EC 1.14.13.43: questin monooxygenase EC 1.14.13.44: 2-hydroxybiphenyl 3-monooxygenase EC 1.14.13.45: Now EC 1.14.18.2, CMP-N-acetylneuraminate monooxygenase EC 1.14.13.46: (-)-menthol monooxygenase EC 1.14.13.47: Now EC 1.14.14.99, (S)-limonene 3-monooxygenase EC 1.14.13.48: Now classified as EC 1.14.14.51, (S)-limonene 6-monooxygenase EC 1.14.13.49: Now classified as EC 1.14.14.52, (S)-limonene 7-monooxygenase EC 1.14.13.50: pentachlorophenol monooxygenase EC 1.14.13.51: 6-oxocineole dehydrogenase EC 1.14.13.52: Now EC 1.14.14.88, isoflavone 3′-hydroxylase EC 1.14.13.53: Now EC 1.14.14.89, 4′-methoxyisoflavone 2′-hydroxylase EC 1.14.13.54: ketosteroid monooxygenase EC 1.14.13.55: Now EC 1.14.14.98, protopine 6-monooxygenase EC 1.14.13.56: Now EC 1.14.14.100, dihydrosanguinarine 10-monooxygenase EC 1.14.13.57: Now EC 1.14.14.101, dihydrochelirubine 12-monooxygenase EC 1.14.13.58: benzoyl-CoA 3-monooxygenase EC 1.14.13.59: L-lysine N6-monooxygenase (NADPH) EC 1.14.13.60: Now included with EC 1.14.13.100, 25-hydroxycholesterol 7α-hydroxylase EC 1.14.13.61: 2-hydroxyquinoline 8-monooxygenase EC 1.14.13.62: 4-hydroxyquinoline 3-monooxygenase EC 1.14.13.63: 3-hydroxyphenylacetate 6-hydroxylase EC 1.14.13.64: 4-hydroxybenzoate 1-hydroxylase EC 1.14.13.65: deleted EC 1.14.13.66: 2-hydroxycyclohexanone 2-monooxygenase EC 1.14.13.67: Now EC 1.14.14.55, quinine 3-monooxygenase EC 1.14.13.68: Now EC 1.14.14.37, 4-hydroxyphenylacetaldehyde oxime monooxygenase EC 1.14.13.69: alkene monooxygenase EC 1.14.13.70: Now EC 1.14.14.154, sterol 14α-demethylase EC 1.14.13.71: Now EC 1.14.14.102, N-methylcoclaurine 3′-monooxygenase EC 1.14.13.72: Now classified as EC 1.14.18.9, methylsterol monooxygenase EC 1.14.13.73: Now EC 1.14.14.103, tabersonine 16-hydroxylase EC 1.14.13.74: Now EC 1.14.14.85, 7-deoxyloganin 7-hydroxylase EC 1.14.13.75: Now EC 1.14.14.104, vinorine hydroxylase EC 1.14.13.76: Now EC 1.14.14.105, taxane 10β-hydroxylase EC 1.14.13.77: Now EC 1.14.14.106, taxane 13α-hydroxylase EC 1.14.13.78: Now EC 1.14.14.86, ent-kaurene monooxygenase EC 1.14.13.79: Now EC 1.14.14.107, ent-kaurenoic acid oxidase EC 1.14.13.80: Now classified as EC 1.14.14.53, (R)-limonene 6-monooxygenase EC 1.14.13.81: magnesium-protoporphyrin IX monomethyl ester (oxidative) cyclase EC 1.14.13.82: vanillate monooxygenase EC 1.14.13.83: precorrin-3B synthase EC 1.14.13.84: 4-hydroxyacetophenone monooxygenase EC 1.14.13.85: Now EC 1.14.14.135, glyceollin synthase EC 1.14.13.86: The activity is covered by EC 1.14.14.87, 2-hydroxyisoflavanone synthase EC 1.14.13.87: Now EC 1.14.14.140, licodione synthase] EC 1.14.13.88: Now EC 1.14.14.81, flavanoid 3,5-hydroxylase EC 1.14.13.89: Now EC 1.14.14.90, isoflavone 2-hydroxylase EC 1.14.13.90: Now EC 1.14.15.21, zeaxanthin epoxidase EC 1.14.13.91: Now EC 1.14.14.136, deoxysarpagine hydroxylase EC 1.14.13.92: phenylacetone monooxygenase EC 1.14.13.93: Now EC 1.14.14.137, (+)-abscisic acid 8-hydroxylase EC 1.14.13.94: Now EC 1.14.14.138, lithocholate 6β-hydroxylase EC 1.14.13.95: Now included with EC 1.14.14.139, 5β-cholestane-3α,7α-diol 12α-hydroxylase EC 1.14.13.96: Now EC 1.14.14.139, 5β-cholestane-3α,7α-diol 12α-hydroxylase EC 1.14.13.97: Now EC 1.14.14.57, taurochenodeoxycholate 6α-hydroxylase EC 1.14.13.98: Now EC 1.14.14.25, cholesterol 24-hydroxylase EC 1.14.13.99: Now EC 1.14.14.26, 24-hydroxycholesterol 7α-hydroxylase EC 1.14.13.100: Now classified as EC 1.14.14.29, 25/26-hydroxycholesterol 7α-hydroxylase EC 1.14.13.101: senecionine N-oxygenase EC 1.14.13.102: Now EC 1.14.14.141, psoralen synthase EC 1.14.13.103: Now EC 1.14.14.142, 8-dimethylallylnaringenin 2-hydroxylase EC 1.14.13.104: Now EC 1.14.14.143, (+)-menthofuran synthase EC 1.14.13.105: monocyclic monoterpene ketone monooxygenase EC 1.14.13.106: now classified as EC 1.14.15.39, epi-isozizaene 5-monooxygenase. EC 1.14.13.107: limonene 1,2-monooxygenase EC 1.14.13.108: Now EC 1.14.14.144, abieta-7,13-diene hydroxylase EC 1.14.13.109: Now EC 1.14.14.145, abieta-7,13-dien-18-ol hydroxylase EC 1.14.13.110: Now EC 1.14.14.146, geranylgeraniol 18-hydroxylase EC 1.14.13.111: methanesulfonate monooxygenase EC 1.14.13.112: Now EC 1.14.14.147, 3-epi-6-deoxocathasterone 23-monooxygenase EC 1.14.13.113: FAD-dependent urate hydroxylase EC 1.14.13.114: 6-hydroxynicotinate 3-monooxygenase EC 1.14.13.115: Now EC 1.14.14.148, angelicin synthase EC 1.14.13.116: Now EC 1.14.14.174, geranylhydroquinone 3-hydroxylase EC 1.14.13.117: Now EC 1.14.14.39, isoleucine N-monooxygenase EC 1.14.13.118: Now EC 1.14.14.38, valine N-monooxygenase EC 1.14.13.119: Now EC 1.14.14.149, 5-epiaristolochene 1,3-dihydroxylase EC 1.14.13.120: Now EC 1.14.14.150, costunolide synthase EC 1.14.13.121: Now EC 1.14.14.151, premnaspirodiene oxygenase EC 1.14.13.122: chlorophyllide-a oxygenase EC 1.14.13.123: Now EC 1.14.14.95, germacrene A hydroxylase EC 1.14.13.124: now classified as EC 1.14.14.40, phenylalanine N-monooxygenase EC 1.14.13.125: Now EC 1.14.14.156, tryptophan N-monooxygenase EC 1.14.13.126: Now EC 1.14.15.16, vitamin D3 24-hydroxylase EC 1.14.13.127: 3-(3-hydroxyphenyl)propanoate hydroxylase EC 1.14.13.128: 7-methylxanthine demethylase EC 1.14.13.129: Now EC 1.14.15.24, β-carotene 3-hydroxylase EC 1.14.13.130: pyrrole-2-carboxylate monooxygenase EC 1.14.13.131: dimethyl-sulfide monooxygenase EC 1.14.13.132: Now EC 1.14.14.17, squalene monooxygenase EC 1.14.13.133: Now EC 1.14.15.32, pentalenene oxygenase EC 1.14.13.134: Now EC 1.14.14.152, β-amyrin 11-oxidase EC 1.14.13.135: 1-hydroxy-2-naphthoate hydroxylase EC 1.14.13.136: Now EC 1.14.14.87, 2-hydroxyisoflavanone synthase EC 1.14.13.137: Now EC 1.14.14.153, indole-2-monooxygenase EC 1.14.13.138: Now EC 1.14.14.157, indolin-2-one monooxygenase EC 1.14.13.139: Now EC 1.14.14.109, 3-hydroxyindolin-2-one monooxygenase EC 1.14.13.140: Now EC 1.14.14.110, 2-hydroxy-1,4-benzoxazin-3-one monooxygenase. EC 1.14.13.141: Now EC 1.14.15.29, cholest-4-en-3-one 26-monooxygenase [(25S)-3-oxocholest-4-en-26-oate forming] EC 1.14.13.142: Now EC 1.14.15.30, 3-ketosteroid 9α-monooxygenase EC 1.14.13.143: Now EC 1.14.14.76 ent-isokaurene C2/C3-hydroxylase EC 1.14.13.144: Now EC 1.14.14.111, 9β-pimara-7,15-diene oxidase EC 1.14.13.145: Now EC 1.14.14.112, ent-cassa-12,15-diene 11-hydroxylase EC 1.14.13.146: taxoid 14β-hydroxylase EC 1.14.13.147: Now EC 1.14.14.182, taxoid 7β-hydroxylase EC 1.14.13.148: trimethylamine monooxygenase EC 1.14.13.149: phenylacetyl-CoA 1,2-epoxidase EC 1.14.13.150: Now EC 1.14.14.113, α-humulene 10-hydroxylase EC 1.14.13.151: Now EC 1.14.14.84, linalool 8-monooxygenase EC 1.14.13.152: Now EC 1.14.14.83, geraniol 8-hydroxylase EC 1.14.13.153: (+)-sabinene 3-hydroxylase EC 1.14.13.154: erythromycin 12-hydroxylase EC 1.14.13.155: α-pinene monooxygenase EC 1.14.13.156: Now EC 1.14.14.133, 1,8-cineole 2-endo-monooxygenase EC 1.14.13.157: Now EC 1.14.14.56, 1,8-cineole 2-exo-monooxygenase EC 1.14.13.158: Now EC 1.14.14.114, amorpha-4,11-diene 12-monooxygenase EC 1.14.13.159: Now EC 1.14.14.24, vitamin D 25-hydroxylase EC 1.14.13.160: (2,2,3-trimethyl-5-oxocyclopent-3-enyl)acetyl-CoA 1,5-monooxygenase EC 1.14.13.161: (+)-camphor 6-exo-hydroxylase EC 1.14.13.162: Now EC 1.14.14.108, 2,5-diketocamphane 1,2-monooxygenase EC 1.14.13.163: 6-hydroxy-3-succinoylpyridine 3-monooxygenase EC 1.14.13.164: withdrawn: see EC 1.13.11.65, carotenoid isomerooxygenase EC 1.14.13.165: Now classified as EC 1.14.14.47, nitric-oxide synthase (flavodoxin) EC 1.14.13.166: 4-nitrocatechol 4-monooxygenase EC 1.14.13.167: 4-nitrophenol 4-monooxygenase EC 1.14.13.168: indole-3-pyruvate monooxygenase EC 1.14.13.169: Now EC 1.14.18.5, sphingolipid C4-monooxygenase EC 1.14.13.170: pentalenolactone D synthase EC 1.14.13.171: neopentalenolactone D synthase EC 1.14.13.172: salicylate 5-hydroxylase EC 1.14.13.173: Now EC 1.14.14.115, 11-oxo-β-amyrin 30-oxidase EC 1.14.13.174: Now EC 1.14.14.116, averantin hydroxylase EC 1.14.13.175: Now EC 1.14.14.117, aflatoxin B synthase EC 1.14.13.176: Now EC 1.14.14.118, tryprostatin B 6-hydroxylase EC 1.14.13.177: Now EC 1.14.14.119, fumitremorgin C monooxygenase EC 1.14.13.178: methylxanthine N1-demethylase EC 1.14.13.179: methylxanthine N3-demethylase EC 1.14.13.180: aklavinone 12-hydroxylase EC 1.14.13.181: 13-deoxydaunorubicin hydroxylase EC 1.14.13.182: 2-heptyl-3-hydroxy-4(1H)-quinolone synthase EC 1.14.13.183: Now EC 1.14.14.120, dammarenediol 12-hydroxylase EC 1.14.13.184: Now EC 1.14.14.121, protopanaxadiol 6-hydroxylase EC 1.14.13.185: Now EC 1.14.15.33, pikromycin synthase EC 1.14.13.186: Now EC 1.14.15.34, 20-oxo-5-O-mycaminosyltylactone 23-monooxygenase EC 1.14.13.187: L-evernosamine nitrososynthase EC 1.14.13.188: Now EC 1.14.15.35, 6-deoxyerythronolide B hydroxylase EC 1.14.13.189: 5-methyl-1-naphthoate 3-hydroxylase EC 1.14.13.190: Now EC 1.14.14.175, ferruginol synthase EC 1.14.13.191: Now EC 1.14.14.70, ent-sandaracopimaradiene 3-hydroxylase EC 1.14.13.192: Now EC 1.14.14.122, oryzalexin E synthase EC 1.14.13.193: Now EC 1.14.14.123, oryzalexin D synthase EC 1.14.13.194: Now EC 1.14.14.78, phylloquinone ω-hydroxylase EC 1.14.13.195: L-ornithine N5-monooxygenase (NADPH) EC 1.14.13.196: L-ornithine N5-monooxygenase [NAD(P)H] EC 1.14.13.197: Now EC 1.14.14.124, dihydromonacolin L hydroxylase EC 1.14.13.198: Now EC 1.14.14.125, monacolin L hydroxylase EC 1.14.13.199: Now EC 1.14.14.79, docosahexaenoic acid ω-hydroxylase EC 1.14.13.200: tetracenomycin A2 monooxygenase-dioxygenase EC 1.14.13.201: Now EC 1.14.14.126, β-amyrin 28-monooxygenase EC 1.14.13.202: Now EC 1.14.14.127, methyl farnesoate epoxidase EC 1.14.13.203: Now EC 1.14.14.128, farnesoate epoxidase EC 1.14.13.204: Now EC 1.14.14.129, long-chain acyl-CoA ω-monooxygenase EC 1.14.13.205: Now EC 1.14.14.80, long-chain fatty acid ω-monooxygenase EC 1.14.13.206: Now EC 1.14.14.130, laurate 7-monooxygenase EC 1.14.13.207: Now EC 1.14.14.31, ipsdienol synthase EC 1.14.13.208: benzoyl-CoA 2,3-epoxidase EC 1.14.13.209: salicyloyl-CoA 5-hydroxylase EC 1.14.13.210: 4-methyl-5-nitrocatechol 5-monooxygenase EC 1.14.13.211: rifampicin monooxygenase EC 1.14.13.212: 1,3,7-trimethyluric acid 5-monooxygenase EC 1.14.13.213: Now EC 1.14.14.131, bursehernin 5-monooxygenase EC 1.14.13.214: Now EC 1.14.14.132, (–)-4′-demethyl-deoxypodophyllotoxin 4-hydroxylase EC 1.14.13.215: protoasukamycin 4-monooxygenase EC 1.14.13.216: asperlicin C monooxygenase EC 1.14.13.217: protodeoxyviolaceinate monooxygenase EC 1.14.13.218: 5-methylphenazine-1-carboxylate 1-monooxygenase EC 1.14.13.219: resorcinol 4-hydroxylase (NADPH) EC 1.14.13.220: resorcinol 4-hydroxylase (NADH) EC 1.14.13.221: Now EC 1.14.15.28, cholest-4-en-3-one 26-monooxygenase [(25R)-3-oxocholest-4-en-26-oate forming] EC 1.14.13.222: aurachin C monooxygenase/isomerase EC 1.14.13.223: 3-hydroxy-4-methylanthranilyl-[aryl-carrier protein] 5-monooxygenase EC 1.14.13.224: violacein synthase EC 1.14.13.225: F-actin monooxygenase EC 1.14.13.226: acetone monooxygenase (methyl acetate-forming) EC 1.14.13.227: propane 2-monooxygenase EC 1.14.13.228: jasmonic acid 12-hydroxylase EC 1.14.13.229: tert-butyl alcohol monooxygenase EC 1.14.13.230: butane monooxygenase (soluble) EC 1.14.13.231: tetracycline 11a-monooxygenase EC 1.14.13.232: 6-methylpretetramide 4-monooxygenase EC 1.14.13.233: 4-hydroxy-6-methylpretetramide 12a-monooxygenase EC 1.14.13.234: 5a,11a-dehydrotetracycline 5-monooxygenase EC 1.14.13.235: indole-3-acetate monooxygenase EC 1.14.13.236: toluene 4-monooxygenase EC 1.14.13.237: aliphatic glucosinolate S-oxygenase EC 1.14.13.238: dimethylamine monooxygenase EC 1.14.13.239: carnitine monooxygenase EC 1.14.13.240: 2-polyprenylphenol 6-hydroxylase EC 1.14.13.241: 5-pyridoxate monooxygenase EC 1.14.13.242: 3-hydroxy-2-methylpyridine-5-carboxylate monooxygenase EC 1.14.13.243: toluene 2-monooxygenase EC 1.14.13.244: phenol 2-monooxygenase (NADH) EC 1.14.13.245: assimilatory dimethylsulfide S-monooxygenase EC 1.14.13.246: 4β-methylsterol monooxygenase EC 1.14.13.247: stachydrine N-demethylase
=== Endodontic treatment === It is a point of interest in endodontics, as it is considered necessary to thoroughly chemomechanically debride the pulp space to remove all necrotic tissue and minimise bacterial load in the pulp space. Ideally, this debridement would terminate exactly at the apical foramen. In reality, determining the exact position of the apical foramen is problematic, requiring radiography and/or use of an electronic apex locator to produce a refined estimate. A tooth may have multiple small accessory canals in the root apex area forming an apical delta which can complicate the endodontic problem. The presence of an apical delta may make successful endodontic treatment less likely. The root tip is removed during apicoectomy to eliminate the apical delta and maximise the chance of successful healing. An apical constriction is often present. In immature teeth the root is not fully formed, leading to an open apex. This is also seen in some pathological teeth. During endodontic treatment, the apical foramen serves to determine the working length. Accurate working length determination is important to decrease or prevent postoperative pain and delayed healing caused by overinstrumentation and overfilling, as well as to avoid inadequate debridement and underfilling of the canal that may result from an under-extended working length short of the apical foramen.
Thus, the current required to keep Vm at a fixed value is a direct reflection of the current flowing through the membrane. Other electronic advances included the use of Faraday cages and electronics with high input impedance, so that the measurement itself did not affect the voltage being measured. The third problem, that of obtaining electrodes small enough to record voltages within a single axon without perturbing it, was solved in 1949 with the invention of the glass micropipette electrode, which was quickly adopted by other researchers. Refinements of this method are able to produce electrode tips that are as fine as 100 Å (10 nm), which also confers high input impedance. Action potentials may also be recorded with small metal electrodes placed just next to a neuron, with neurochips containing EOSFETs, or optically with dyes that are sensitive to Ca2+ or to voltage.
Sources: en.wikipedia.org
Xi identifies environmental protection as one of China's five major priorities for national progress. Xi has popularized a metaphor of "two mountains" to emphasize the importance of environmental protection. The concept is that a mountain made of gold or silver is valuable, but green mountains with clear waters are more valuable. The slogan's meaning is that economic development priorities must also provide for economic protection. In September 2020, Xi announced that China would "strengthen its 2030 climate target (NDC), peak emissions before 2030 and aim to achieve carbon neutrality before 2060." If accomplished, this would lower the expected rise in global temperature by 0.2–0.3 °C – "the biggest single reduction ever estimated by the Climate Action Tracker." Xi mentioned the link between the COVID-19 pandemic and nature destruction as one of the reasons for the decision, saying that "Humankind can no longer afford to ignore the repeated warnings of nature." On 27 September 2020, Chinese scientists presented a detailed plan how to achieve the target. In September 2021, Xi announced that China will not build "coal-fired power projects abroad", which was said to be potentially "pivotal" in reducing emissions. The Belt and Road Initiative did not include financing such projects in the first half of 2021. Xi did not attend COP26 personally. However, a Chinese delegation led by climate change envoy Xie Zhenhua did attend. During the conference, the United States and China agreed on a framework to reduce GHG emission by co-operating on different measures.
== United States == In the United States, the Food and Drug Administration (FDA) has determined that while such tests qualify as medical devices, these products could enter the market without prior approval from the agency. In 2014, the FDA announced that it would start regulating some LDTs. In general, however, it has not done so, as of April 2019. As LDTs do not require FDA 510(k) clearance required by other diagnostic tests, they have been viewed as a regulatory loophole by opponents.
Nordazepam and other sedative–hypnotic drugs are detected frequently in cases of people suspected of driving under the influence of drugs. Many drivers have blood levels far exceeding the therapeutic dose range, suggesting benzodiazepines are commonly used in doses higher than the recommended doses.
== Structure == Both endomorphins-1 and 2 are tetrapeptides, consisting of four amino acids. Endomorphin-1 has the amino acid sequence of Tyr-Pro-Trp-Phe, while endomorphin-2 has a sequence of Tyr-Pro-Phe-Phe. The specific amino acids in these sequences dictate the folding and resultant behavior, namely the ability to bind μ-opioid receptors, of these molecules.
Sources: en.wikipedia.org
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.
It is not classified as a vasodilator, and its proposed site of action is the central nervous system rather than peripheral vessels. Some trial participants show small transient blood pressure changes. Whether those changes arise centrally or through another route remains an open question.
Most evidence comes from animal models and from indirect human outcomes such as self-reported desire. Direct measurements of receptor occupancy or signalling in the human brain are not available. Published reviews therefore present a plausible pathway rather than a confirmed sequence of events.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.